Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

This study has been completed.
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc. Identifier:
First received: February 14, 2011
Last updated: November 4, 2013
Last verified: November 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2012
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)